Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer/GSK vardenafil 

Executive Summary

Trade name for erectile dysfunction disorder drug vardenafil is Levitra, Bayer and GlaxoSmithKline announce. Bayer had earlier referred to the drug as Nuviva; the name was one of several submitted to FDA for approval (1"The Pink Sheet" March 18, p. 29). The companies received an "approvable" letter for vardenafil in July; approval is expected in 2003 (2"The Pink Sheet" July 29, In Brief)...

You may also be interested in...



Analysts Presentations, Conference Calls In Brief

Bayer's vardenafil is Nuviva: Bayer's brand name for vardenafil is Nuviva, R&D Board Committee Chair Frank Morich, PhD, announced during a press briefing March 13. An NDA for the erectile dysfunction drug is pending at FDA; Bayer expects approval in the second half of 2002. Nuviva will be co-promoted with GlaxoSmithKline...

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

US FDA Eases Changes For Certain Sterile Injectable Container Closure Materials

To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.

UsernamePublicRestriction

Register

LL009864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel